These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 34716560)

  • 1. Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study.
    Komatsu Y; Hironaka S; Tanizawa Y; Cai Z; Piao Y; Boku N
    Adv Ther; 2022 Jan; 39(1):296-313. PubMed ID: 34716560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in japan: a retrospective database cohort study.
    Yoshikawa T; Kikko Y; Makino R; Kimijima Y; Nishiyama E; Matsuda Y; Casaes Teixeira B; Tejada M; Carroll R; Hironaka S
    Gastric Cancer; 2024 Jul; 27(4):827-839. PubMed ID: 38689045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.
    Nishina T; Boku N; Kurokawa Y; Sasaki K; Machida R; Yoshikawa T
    Jpn J Clin Oncol; 2024 Oct; 54(10):1100-1106. PubMed ID: 39180720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine for the treatment of advanced gastric cancer.
    Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.
    Kawakami H; Takeno A; Endo S; Makari Y; Kawada J; Taniguchi H; Tamura S; Sugimoto N; Kimura Y; Tamura T; Fujitani K; Sakai D; Shimokawa T; Kurokawa Y; Satoh T
    Oncologist; 2018 Dec; 23(12):1411-e147. PubMed ID: 30115736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
    Shinozaki E; Makiyama A; Kagawa Y; Satake H; Tanizawa Y; Cai Z; Piao Y
    PLoS One; 2021; 16(2):e0246160. PubMed ID: 33556095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
    Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
    Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
    Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
    Arai H; Iwasa S; Boku N; Kawahira M; Yasui H; Masuishi T; Muro K; Minashi K; Hironaka S; Fukuda N; Takahari D; Nakajima TE
    BMC Cancer; 2019 Jul; 19(1):652. PubMed ID: 31269916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
    Shitara K; Mizota A; Matsuo K; Sato Y; Kondo C; Takahari D; Ura T; Tajika M; Muro K
    Gastric Cancer; 2013 Jan; 16(1):48-55. PubMed ID: 22362376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
    Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
    Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer.
    Jeon Y; Lim SH; Lee J; Kang WK; Jang JY; Jeong SY; Choi D; Kim ST
    J Gastrointest Oncol; 2023 Dec; 14(6):2346-2353. PubMed ID: 38196521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
    Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
    Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
    BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
    Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study.
    Cao ND; Zhu XH; Ma FQ; Xu Y; Dong JH; Qin MM; Liu TS; Zhu CC; Guo WJ; Ding HH; Guo YB; Liu LK; Song JJ; Wu JP; Cheng YL; Zeng L; Zhao AG
    Chin J Integr Med; 2024 Jun; 30(6):489-498. PubMed ID: 38801641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107.
    Sato K; Kunisaki C; Kosaka T; Takagawa R; Takahashi M; Izumisawa Y; Miyamoto H; Sato S; Tanaka Y; Yamaguchi N; Kimura J; Ono HA; Makino H; Akiyama H; Endo I
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):939-943. PubMed ID: 28913549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
    Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.